Updated: Oct 15
Medically reviewed by ChinaCureLink Team
Table of Content
Why This Case Matters
Maisha, a young patient from Pakistan with relapsed B-ALL, traveled to China after her leukemia returned following years of treatment at home. Her case demonstrates a treatment pathway that combined CAR-T cell therapy to control relapsed leukemia with a subsequent allogeneic stem cell transplant once a fully matched unrelated donor was identified. For international patients facing relapsed or refractory blood cancers, ChinaCureLink can help coordinate specialist case review, hospital matching, medical records, and the practical arrangements required to pursue treatment in China.
Key Takeaways |
|
Patient Background
Maisha was diagnosed with acute B-cell lymphoblastic leukemia in 2014 at a hospital in Islamabad, Pakistan. She underwent approximately two and a half years of treatment, including eight courses of chemotherapy, and her leukemia entered remission.
In May 2017, however, the disease relapsed.
Her family began looking internationally for another treatment option. After learning about a specialized hematology hospital in China through their network and researching treatment options online, they contacted the hospital's international patient team. Following multiple consultations and a comprehensive review, the family traveled to China, where Maisha was admitted on August 18, 2017.
At admission, bone marrow testing showed measurable residual leukemia of 3.16% by flow cytometry. This meant she did not yet meet the clinical conditions required to proceed directly to stem cell transplantation.
The Care Team and Approach
The medical team developed a two-stage strategy: first use CAR-T cell therapy to bring the leukemia under control, then bridge to an allogeneic hematopoietic stem cell transplant.
Dr. Amina Rahman (pseudonym), who oversaw the CAR-T component of Maisha's treatment, explained that CAR-T therapy was selected because she was experiencing a second hematological relapse and still had measurable leukemia in her bone marrow.
On September 1, 2017, Maisha received her CAR-T cell infusion. Fifteen days later, a bone marrow examination showed no detectable measurable residual disease by flow cytometry. This response created the opportunity to move toward potentially definitive treatment with a stem cell transplant.
At the same time, the transplant team searched for a compatible donor through China's national bone marrow donor registry. The search identified an unrelated volunteer donor from Xuzhou whose HLA type matched Maisha at all 10 tested loci.
Dr. Sara Malik (pseudonym) led the transplant component of her care. With a 10/10 HLA match identified, the team proceeded with conditioning followed by allogeneic hematopoietic stem cell transplantation.
The transplant also involved an extraordinary cross-border logistical effort. The donor's stem cells were collected in Xuzhou on December 5, 2017, and hospital staff immediately transported the cells by high-speed rail to Beijing, where they were infused into Maisha that same evening.
Treatment Timeline/ Process
In Pakistan
2014: Diagnosed with acute B-cell lymphoblastic leukemia at a hospital in Islamabad.
2014–2017: Received approximately two and a half years of treatment, including eight courses of chemotherapy.
Achieved an initial remission and was discharged from treatment.
May 2017: Leukemia relapsed.
Arrival in China
August 18, 2017: Arrived in China and was admitted to a specialized hematology hospital.
Initial bone marrow testing showed 3.16% measurable residual disease by flow cytometry.
A multidisciplinary team determined that she required additional disease control before proceeding to transplantation.
CAR-T Therapy
September 1, 2017: Received CAR-T cell therapy as the first stage of treatment.
Day 15: Bone marrow testing showed no detectable measurable residual disease by flow cytometry, establishing a bridge toward transplantation.
Stem Cell Transplant
Following CAR-T treatment, a donor search identified an unrelated volunteer with a 10/10 HLA match.
November 17, 2017: Began conditioning before transplantation.
December 5, 2017: The donor's stem cells were collected in Xuzhou and transported to Beijing.
December 5, 2017: Received the allogeneic hematopoietic stem cell infusion.
Day +7: Platelet engraftment was confirmed.
Day +15: White blood cell engraftment was confirmed.
December 22, 2017: Successfully left the transplant unit after more than 30 days of inpatient transplant care.
Recovery and Follow-Up
Approximately two months after transplantation, bone marrow remained in remission.
Flow cytometry showed 0% measurable residual disease, with 100% donor-type hematopoiesis.
She had mild pneumonia but no acute graft-versus-host disease at that stage.
March 5, 2018: After more than six months of treatment in China, she was discharged.
Outcome
Following CAR-T therapy, Maisha's measurable residual leukemia became undetectable by flow cytometry, allowing her treatment to proceed to allogeneic stem cell transplantation.
After transplantation, her blood counts recovered with platelet engraftment on day +7 and white blood cell engraftment on day +15. At approximately two months post-transplant, her bone marrow remained in remission, with flow cytometry showing 0% measurable residual disease and 100% donor-type hematopoiesis. She had mild pneumonia but no acute graft-versus-host disease at that point.
After more than six months of treatment in China, Maisha was discharged on March 5, 2018. Her care team emphasized the importance of ongoing monitoring, infection prevention, medication adherence, nutrition, and regular blood and biochemical testing after discharge.
How ChinaCureLink Can Help International Patients to Access This Treatment
Maisha's case illustrates how complex blood-cancer treatment can require several stages rather than a single intervention. For an international patient with relapsed B-ALL, access may involve specialist assessment, advanced cellular therapy, donor identification, transplantation, and intensive post-treatment monitoring.
ChinaCureLink helps international patients navigate this process by arranging an initial medical case review, translating and organizing medical records, matching patients with appropriate specialist hospitals, coordinating treatment scheduling, and supporting the practical logistics of traveling to China for care.
For patients with relapsed or refractory leukemia who need an assessment for CAR-T therapy, stem cell transplantation, or a combination of approaches, the first step is a review of the patient's diagnosis, pathology, treatment history, current disease status, and transplant eligibility.
Get a Second Opinion Before Fly to China
For suitable cases, ChinaCureLink can then coordinate an online consultation with the specialist to discuss the technical treatment details directly. The purpose is to help the patient understand which treatment option and which specialist center may be most appropriate before making an international treatment decision.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
★★★★☆ Sarah Zhang · Canada· Jul 2024 · Verified “The interpreter during the video call was fantastic — super professional and answered all our questions clearly and quickly. The professor was also very patient and gave us detailed and honest guidance on our treatment options.” |
★★★★★ Andrew Goh · Singapore · Aug 2024 · Verified “My first contact with Medebound was over a year ago. Jason has always been responsive, even when I wasn't ready to proceed. When I finally did, the consultation was seamlessly arranged and the specialist was outstanding.” |
★★★★★ Daniel Wong · Singapore · Aug 2024 · Verified “I have dry eye and nothing seemed to be working, even with different medications. I heard about a medication from the U.S. that’s supposed to be really effective, but I didn’t want to try it without talking to a doctor first. MEDEBOUND connected me with a top ophthalmologist in the U.S. and it was so reassuring to get their expert advice.” |
★★★★☆ Pongsakorn · Thailand · Feb 2025 · Verified “Kiki at Medebound is amazing — so professional and helpful! They got my video consultation with an MD Anderson expert set up super fast, within just 5 working days. I am so grateful for their support.” |
Frequently Asked Questions
Can an international patient with relapsed B-ALL access CAR-T therapy in China?
Eligibility depends on the patient's leukemia subtype, current disease status, prior treatments, laboratory results, and the specific CAR-T program available at the treating hospital. An individual specialist assessment is required before treatment can be planned.
Can CAR-T therapy be followed by a stem cell transplant for relapsed leukemia?
In some cases, CAR-T therapy can be used to bring relapsed leukemia under better disease control before proceeding to allogeneic stem cell transplantation. Whether this approach is appropriate depends on the patient's response, overall condition, donor availability, and transplant assessment.
How can a Pakistani patient arrange leukemia treatment in China?
The process typically begins with a remote review of medical records, pathology, bone marrow results, treatment history, and current disease status. ChinaCureLink can coordinate the medical review, specialist matching, hospital communication, treatment scheduling, and travel-related logistics for patients accepted for treatment.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
Disclaimer
This account reflects one patient's individual experience, which will vary by case, diagnosis stage, and other clinical factors. ChinaCureLink facilitates access to hospitals and treatment coordination — we do not provide medical care ourselves, and this content is not medical advice. Patients and families should consult a qualified hematologist-oncologist before making treatment decisions.
